Michael Heinrich

Professor

  • 33900 Citations
  • 80 h-Index
1985 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Michael Heinrich is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study

Von Mehren, M., George, S., Heinrich, M. C., Schuetze, S. M., Yap, J. T., Yu, J. Q., Abbott, A., Litwin, S., Crowley, J., Belinsky, M., Janeway, K. A., Hornick, J. L., Flieder, D. B., Chugh, R., Rink, L. & Van Den Abbeele, A. D., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1837-1845 9 p.

Research output: Contribution to journalArticle

  • Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

    Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

    Research output: Contribution to journalArticle

  • Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

    Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., Yan, D., Senina, A. V., Qiang, W., Kelley, T. W., Szankasi, P., Heinrich, M. C., Tyner, J. W., Rea, D., Cayuela, J. M., Kim, D. W. & 4 others, Tognon, C. E., O'Hare, T., Druker, B. J. & Deininger, M. W., Oct 14 2019, In : Cancer Cell. 36, 4, p. 431-443.e5

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

    Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., Raut, C. P., Presnell, A., McKinley, A., Heinrich, M. C., Czaplinski, J. T., Sicinska, E., Bauer, S., George, S. & Fletcher, J. A., Mar 19 2019, In : British Journal of Cancer. 120, 6, p. 612-620 9 p.

    Research output: Contribution to journalArticle

  • 10 Scopus citations

    Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

    Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., Raut, C. P., Presnell, A., McKinley, A., Heinrich, M. C., Czaplinski, J. T., Sicinska, E., Bauer, S., George, S. & Fletcher, J. A., Jul 30 2019, In : British Journal of Cancer. 121, 3, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • 1 Scopus citations